Cargando…

Endocrine late effects in survivors of infantile acute lymphoblastic leukemia

Infantile acute lymphoblastic leukemia (ALL) is a rare disease. In survivors, endocrine late effects, such as growth disorder and hypothyroidism, have been reported, but gonadal function remains unclear. Infantile ALL frequently requires transplantation and higher doses of alkylating agents, even in...

Descripción completa

Detalles Bibliográficos
Autores principales: Akisada, Hiroko, Hasegawa, Mari, Ishihara, Takashi, Akisada, Naohiro, Ochi, Satoshi, Nogami, Keiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society for Pediatric Endocrinology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068619/
https://www.ncbi.nlm.nih.gov/pubmed/37020698
http://dx.doi.org/10.1297/cpe.2022-0037
_version_ 1785018697310535680
author Akisada, Hiroko
Hasegawa, Mari
Ishihara, Takashi
Akisada, Naohiro
Ochi, Satoshi
Nogami, Keiji
author_facet Akisada, Hiroko
Hasegawa, Mari
Ishihara, Takashi
Akisada, Naohiro
Ochi, Satoshi
Nogami, Keiji
author_sort Akisada, Hiroko
collection PubMed
description Infantile acute lymphoblastic leukemia (ALL) is a rare disease. In survivors, endocrine late effects, such as growth disorder and hypothyroidism, have been reported, but gonadal function remains unclear. Infantile ALL frequently requires transplantation and higher doses of alkylating agents, even in the absence of transplantation. Some studies in childhood cancer survivors reported that a cyclophosphamide equivalent dose (CED) of > 20 g/m(2) was associated with testosterone deficiency in boys and > 8 g/m(2) with ovarian dysfunction in girls. We retrospectively reviewed the treatment and endocrine function of 6 infantile ALL survivors treated at our hospital using their medical records. The patients’ age at the time of the study was between 12 and 26 yr. One patient had 0 transplant, four of them had 1 transplant, and one had 2 transplants, with CEDs of 3, 9–11, and 24 g/m(2) respectively. Two patients had short stature, and two patients experienced hypothyroidism. All three girls with a CED of 9–11 g/m(2) had primary hypogonadism, and the boy with a CED of 24 g/m(2) had high LH and FSH levels, suggesting testosterone deficiency and spermatogenesis disorders. In conclusion, gonadal function, growth and thyroid function should be carefully monitored in infantile ALL, and CED may be useful for predicting the development of hypogonadism.
format Online
Article
Text
id pubmed-10068619
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Japanese Society for Pediatric Endocrinology
record_format MEDLINE/PubMed
spelling pubmed-100686192023-04-04 Endocrine late effects in survivors of infantile acute lymphoblastic leukemia Akisada, Hiroko Hasegawa, Mari Ishihara, Takashi Akisada, Naohiro Ochi, Satoshi Nogami, Keiji Clin Pediatr Endocrinol Original Article Infantile acute lymphoblastic leukemia (ALL) is a rare disease. In survivors, endocrine late effects, such as growth disorder and hypothyroidism, have been reported, but gonadal function remains unclear. Infantile ALL frequently requires transplantation and higher doses of alkylating agents, even in the absence of transplantation. Some studies in childhood cancer survivors reported that a cyclophosphamide equivalent dose (CED) of > 20 g/m(2) was associated with testosterone deficiency in boys and > 8 g/m(2) with ovarian dysfunction in girls. We retrospectively reviewed the treatment and endocrine function of 6 infantile ALL survivors treated at our hospital using their medical records. The patients’ age at the time of the study was between 12 and 26 yr. One patient had 0 transplant, four of them had 1 transplant, and one had 2 transplants, with CEDs of 3, 9–11, and 24 g/m(2) respectively. Two patients had short stature, and two patients experienced hypothyroidism. All three girls with a CED of 9–11 g/m(2) had primary hypogonadism, and the boy with a CED of 24 g/m(2) had high LH and FSH levels, suggesting testosterone deficiency and spermatogenesis disorders. In conclusion, gonadal function, growth and thyroid function should be carefully monitored in infantile ALL, and CED may be useful for predicting the development of hypogonadism. The Japanese Society for Pediatric Endocrinology 2023-02-03 2023 /pmc/articles/PMC10068619/ /pubmed/37020698 http://dx.doi.org/10.1297/cpe.2022-0037 Text en 2023©The Japanese Society for Pediatric Endocrinology https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. (CC-BY-NC-ND 4.0: http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ).
spellingShingle Original Article
Akisada, Hiroko
Hasegawa, Mari
Ishihara, Takashi
Akisada, Naohiro
Ochi, Satoshi
Nogami, Keiji
Endocrine late effects in survivors of infantile acute lymphoblastic leukemia
title Endocrine late effects in survivors of infantile acute lymphoblastic leukemia
title_full Endocrine late effects in survivors of infantile acute lymphoblastic leukemia
title_fullStr Endocrine late effects in survivors of infantile acute lymphoblastic leukemia
title_full_unstemmed Endocrine late effects in survivors of infantile acute lymphoblastic leukemia
title_short Endocrine late effects in survivors of infantile acute lymphoblastic leukemia
title_sort endocrine late effects in survivors of infantile acute lymphoblastic leukemia
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068619/
https://www.ncbi.nlm.nih.gov/pubmed/37020698
http://dx.doi.org/10.1297/cpe.2022-0037
work_keys_str_mv AT akisadahiroko endocrinelateeffectsinsurvivorsofinfantileacutelymphoblasticleukemia
AT hasegawamari endocrinelateeffectsinsurvivorsofinfantileacutelymphoblasticleukemia
AT ishiharatakashi endocrinelateeffectsinsurvivorsofinfantileacutelymphoblasticleukemia
AT akisadanaohiro endocrinelateeffectsinsurvivorsofinfantileacutelymphoblasticleukemia
AT ochisatoshi endocrinelateeffectsinsurvivorsofinfantileacutelymphoblasticleukemia
AT nogamikeiji endocrinelateeffectsinsurvivorsofinfantileacutelymphoblasticleukemia